ClinicalTrials.gg
RecruitingNCT05271682Updated May 16, 2023

A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple Myeloma

A Phase 1 interventional study of FHND6091 in Multiple Myeloma, sponsored by Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.. Recruiting at 6 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-16.

Sponsored by Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 10 months ago, but the record still lists the study as recruiting.
  • Started Dec 2021; still recruiting 4 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 448 studies in Multiple Myeloma with a site in China — 238 open to participants now, 275 under way, 47 of them phase 3. Multiple Myeloma · China.

Planned enrollment
201st of 406
40 · median 40
Started
2021
with 42 others
Phase 1
151 of 448
73 open now
Primary completion
2023-12
later than 6 of 274 live
Registered
171st of 448
by date

Among the 448 studies in Multiple Myeloma with a site in China, this one is the 201st largest by planned enrollment of the 406 interventional ones that give a count, is one of 43 that started in 2021, is one of 151 in phase 1, reaches primary completion later than 6 of the 274 other live ones, and was the 171st registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

238 of the 448 studies in Multiple Myeloma with a site in China are open now. Recruiting first, the newest first:

233 more — sign in →

All 238 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 448 studies in Multiple Myeloma with a site in China, or all of them as a file.
02

Study summary

This is a phase I, first in human, single arm, open label study that will assess safety, tolerability and clinical activity of FHND6091 when taken orally on a weekly dosing schedule by patients with relapsed and refractory multiple myeloma (RRMM).The study will consist of two parts: dose escalation (Part 1) and dose expansion (Part 2).The dose escalation (Part 1) of the study will evaluate the safety and tolerability of FHND6091 using a dose escalation scheme to establish a maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D). And the dose expansion (Part B) of the study will further evaluate the safety, pharmacokinetics (PK)/ pharmacodynamics (PD), and efficacy of FHND6091 at two selected dose levels to characterize the safety, tolerability and efficacy of FHND6091.

A total of 40 evaluable participants will be enrolled in the study. The participants receiving treatment in part 1 and part 2 may continue combination treatment for a total of up to 12 cycles. After 12 cycles of therapy, the participants will continue treatment until the occurrence of PD, intolerable AEs, consent withdrawal, death or end of study based on the judgement of investigator's assessment.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must give written .
  • Male or female patients 18 years or older.
  • (ECOG) Performance Status of 0, 1 or 2.
  • of at least 12 weeks.
  • Patients with multiple myeloma who have , intolerance or refuse treatment following at least 3 regimens or that must include an IMID (lenalidomide or thalidomide), a proteasome inhibitor (bortezomib) , a CD38-targeted mAbs and . Patients must have received transplant therapy or are not suitable for transplant.
  • For Patients With Relapsed Refractory Multiple Myeloma must have defined by at least 1 of the following 2 measurements: Serum M-protein ≥ 5 g/L, or Urine M-protein ≥ 200 mg/24 hours. For patients with serum free light chain as measurable disease: Serum immunoglobulin free light chain ≥10 mg/dL and abnormal serum immunoglobulin kappa to lambda free light chain ratio.
  • Clinical laboratory values as specified below within 14 days before the first dose of study drug:

    1. ≥ 75 g/L, ≥ 1.0 x 10E9/L and count ≥ 75 x 10E9/L without blood transfusion, EPO or G-CSF and other medical support for at least 14 days prior to receiving screening.
    2. Total levels ≤ 2 x , (SGOT) and ALT (SGPT) ≤ 2 x ULN.
    3. Calculated or measured (CrCl) of ≥ 30 mL/minute as calculated by Cockcroft-Gault method.
    4. Corrected Serum Calcium ≤ ULN.
  • For man and women of : agreement to remain abstinent or use , during the treatment period (including treatment interruptions) and for at least 180 days after the last dose of FHND6091 was administered. Women of childbearing potential should be negative by serum pregnancy test within 7 days prior dosing.

Exclusion criteria

Exclusion Criteria:

  • Documented allergy to proteasome inhibitor or ;
  • Patients with peripheral neuropathy ≥ Grade 2 or Grade 1 peripheral neuropathy with pain.
  • Patients with diarrhea > Grade 1 (Increase of \<4 stools per day over baseline; mild increase in ostomy output compared to baseline).
  • Patients received chemotherapy, radiation therapy, targeted therapy, immunotherapy or other systemic anticancer therapy within 14 days prior FHND6091 treatment.
  • Patients received ixazomib treatment within 5 elimination half-life prior first dose of FHND6091 treatment.
  • Patients received stem cell transplantation or autologous stem cell transplant with 12 weeks before screening.
  • Patients with symptomatic , or, spinal cord compression or central nervous system (CNS) injuries/abnormalities based on investigator judgement.
  • Evidence of severe or uncontrolled systemic diseases (eg, unstable or uncompensated respiratory, hepatic or renal disease), or receive major surgery.
  • Patients with unstable hypertension after drug treatment (SBP ≥140 mmHg, DBP ≥90 mmHg ) or heart failure, myocardial ischemia or myocardial infarction, unstable angina, arrhythmia (The interval (Fridericia formula) interval (QTcF) > 470 msec for females and > 450 msec for men in (ECG)).
  • Patients with active, or a history of immunodeficiency, including positive or other acquired and congenital immunodeficiency diseases, or a history of solid organ transplant.
  • Patients with a history of other serious underlying diseases, such as: a, history of a clear neurological or psychiatric disorder, including epilepsy or dementia. b, surface antigen positivity (subjects with documented laboratory evidence of HBV clearance may be enrolled) or positive antibody. c, presence of infection requiring systemic treatment.
  • Systemic treatment with strong inhibitors of of or strong CYP3A4 inducers within 5 elimination half-life prior first dose of FHND6091 treatment.
  • Patients have not recovered (ie, ≤ Grade 1 toxicity by 5.0) from the reversible effects of prior antineoplastic therapy (except for alopecia )
  • Patients with other ;
  • Treatment with any products within 28 days before the first dose of study treatment
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Part 1: 0.4 mg

    FHND6091, 0.4 mg, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period

    Drug: FHND6091

  • Experimental
    Part 1: 0.8 mg

    FHND6091, 0.8 mg, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period

    Drug: FHND6091

  • Experimental
    Part 1: 1.4 mg

    FHND6091, 1.4 mg, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period

    Drug: FHND6091

  • Experimental
    Part 1: 2.0 mg

    FHND6091, 2.0 mg, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period

    Drug: FHND6091

  • Experimental
    Part 1: 2.8 mg

    FHND6091, 2.8 mg, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period

    Drug: FHND6091

  • Experimental
    Part 1: 3.6 mg

    FHND6091, 3.6 mg, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period

    Drug: FHND6091

  • Experimental
    Part 2: lower dose expansion

    FHND6091, a lower dose, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period

    Drug: FHND6091

  • Experimental
    Part 2: MTD pr MTD-1 dose expansion

    FHND6091, MTD or MTD-1 dose, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period

    Drug: FHND6091

Interventions

  • DrugFHND6091

    FHND6091 capsules

06

What researchers measure

Primary outcomes

  1. Number of Participants Reporting One or More Treatment-Emergent Adverse Events and Serious Adverse Events

    An Adverse Event is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A Serious Adverse Event (SAE) was any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.

    Time frame: Baseline to 28 days after first dose of FHND6091 administration

Secondary outcomes

  1. Complete Response/Stringent Complete Response (CR/sCR) Rate

    CR/sCR to FHND6091, according to international myeloma working group (IMWG) criteria

    Time frame: Baseline to 12 months after first dose of FHND6091 administration

  2. Rate of Very Good Partial Response (VGPR) or Better

    VGPR to FHND6091, according to international myeloma working group (IMWG) criteria

    Time frame: Baseline to 12 months after first dose of FHND6091 administration

  3. Partial Response (PR)

    PR to FHND6091, according to international myeloma working group (IMWG) criteria

    Time frame: Baseline to 12 months after first dose of FHND6091 administration

  4. Cmax: Maximum Observed Plasma Concentration for FHND6091

    Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve for FHND6091

    Time frame: Days 1 and 15 of Cycle 1 (each cycle is 28 days)

  5. Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for FHND6091

    Time to reach the maximum observed plasma concentration (Cmax), equal to time to Cmax

    Time frame: Days 1 and 15 of Cycle 1 (each cycle is 28 days)

  6. AUC(0-168): Area Under the Plasma Concentration-Time Curve From Time 0 to 168 Hours Postdose for FHND6091

    AUC(0-168) is a measure of the area under the plasma concentration-time curve over the dosing interval (tau) (AUC\[0-tau\]), where tau is the length of the dosing interval - 168 hours in this study)

    Time frame: Days 1 and 15 of Cycle 1 (each cycle is 28 days)

07

Study locations

6 of 6 sites recruiting
  • The first affiliated hospital of bengbu medical college
    Bengbu, Anhui 233000, China
    Recruiting
    • Huan Zhou, Ph.D · Contact13665527160
    • Junfeng Zhu, MD · Principal investigator
    • Huan Zhou, MD · Principal investigator
  • Henan Cancer Hospital
    Zhengzhou, Henan 450003, China
    Recruiting
    • Yuefang Chen · Contacthnszlyygcp@163.com · 0371-65588007
    • Baijun Fang, M.D. · Principal investigator
  • The Third Hosptial of Changsha
    Changsha, Hunan, China
    Recruiting
    • Yu Cuihua · Contact(0731) 8517 1463
    • shen Zengmei · Principal investigator
  • The Affilitated Hospital of Xuzhou Medical University
    Xuzhou, Jiangsu, China
    Recruiting
    • Jiang Haijing · Contact0516-23698580
    • Yan Zhiling, MD · Principal investigator
  • Xi'an Central Hospital
    Xi'an, Shaanxi, China
    Recruiting
    • Zhang Yi · Contact029-81629000
    • Song Yanping, MD · Principal investigator
  • Ruijin Hospital
    Shanghai, 200025, China
    Recruiting
    • Meiwen Shu · Contactiec2020@rjh.com.cn · 021-34188900
    • Jianqing Mi, M.D. · Principal investigator
    • Yi Tao, M.D. · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Dec 2023, 24 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's planned 24 months is below that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2022
First posted
Mar 9, 2022
StartActual
Dec 22, 2021
Primary completionEst.
Dec 31, 2023
CompletionEst.
Dec 31, 2024
Last update
May 16, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05271682
Responsible party
Sponsor
First posted
Mar 9, 2022
Start date
Dec 22, 2021
Primary completion
Dec 31, 2023 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
May 16, 2023

Study contacts

Minghong Shang
Contact
shangmh@ctfh.com.cn
025-57033246
Jianqin Mi, M.D.
principal investigator · Ruijin Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion